ObsEva (NASDAQ:OBSV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
OBSV has been the subject of several other reports. Leerink Swann increased their price objective on shares of ObsEva from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of ObsEva in a research report on Friday, March 9th. BMO Capital Markets reaffirmed a “buy” rating and issued a $24.00 price objective on shares of ObsEva in a research report on Tuesday, February 27th. Credit Suisse Group reaffirmed a “buy” rating and issued a $18.00 price objective (up from $16.00) on shares of ObsEva in a research report on Tuesday, February 27th. Finally, ValuEngine raised shares of ObsEva from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. ObsEva presently has an average rating of “Buy” and a consensus price target of $20.00.
ObsEva (NASDAQ:OBSV) last announced its quarterly earnings data on Wednesday, May 16th. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.08). research analysts anticipate that ObsEva will post -2.07 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of OBSV. Sofinnova Ventures Inc purchased a new position in ObsEva during the 1st quarter worth approximately $64,096,000. Omega Fund Management LLC purchased a new position in ObsEva during the 4th quarter worth approximately $9,760,000. First Manhattan Co. purchased a new position in ObsEva during the 4th quarter worth approximately $9,760,000. Sofinnova Management VIII L.L.C. raised its position in ObsEva by 26.7% during the 4th quarter. Sofinnova Management VIII L.L.C. now owns 4,749,623 shares of the company’s stock worth $46,356,000 after buying an additional 1,000,000 shares during the last quarter. Finally, VHCP Management II LLC raised its position in ObsEva by 41.9% during the 4th quarter. VHCP Management II LLC now owns 1,988,843 shares of the company’s stock worth $19,411,000 after buying an additional 587,500 shares during the last quarter. 66.07% of the stock is owned by institutional investors.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.